HOME
DISEASE STATE EDUCATION
- All
- Cirrhosis
- HBV
- HCC
- HCV
- HDV
- HE
- HRS
- MASH
- PBC
- Pediatric Liver Disease
- Wilson’s Disease
About CLDF
EVENTS
- Conferences
- Meeting Series

Anchored in expertise. Advancing knowledge. Elevating liver care.

See what Everyone’s Talking About

February 26-28, 2026

Gaylord Pacific Resort & Convention Center

Chula Vista, CA

Events

Breakthroughs in MASH Diagnosis and Management - A Liver Connect City Series

UPDATES in GI

NEW ENGLAND GI & LIVER UPDATE

3rd Annual Rush Liver Conference

Mid Atlantic GI & Liver Conference

Breakthroughs in MASH Diagnosis and Management - A Liver Connect City Series

Breakthroughs in MASH Diagnosis and Management - A Liver Connect City Series

Clinical Insights

MASH APP Preceptorship

Saturday, October 25th, at Atlanta, GA, USA.

Resmetirom: The First FDA-Approved Therapy for MASH

Understanding Lipodystrophy – A Primer for Hepatologists

PBC vs. PSC – Spotting the Differences

HCC - New Paradigms in Management

Alcoholic Liver Disease – A Growing Epidemic

NITs in MASH & MASLD – The Future of Early Detection

Pediatric Cholestatic Diseases & PFIC – What Every Hepatologist Should Know

Wilson Disease – A Condition Every Hepatologist Must Recognize

Viral Hepatitis – What’s Changing?

Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA

Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively

Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically

Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression

Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy

Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy

Building a Sense of Urgency for PBC Patient Evaluation/Monitoring

Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis

Health-Related Quality of Life and Emerging Therapies In PBC

CLDF KOL Conversations: MASLD Positioning New and Emerging Therapies

CLDF/GHAPP Podcast: Cirrhosis and Hepatic Encephalopathy

View All

Featured Resources

View All Modules

pcbimg

Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives

Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives

pcbimg

Clinicians and Patients Confront Practical Issues in Wilson Disease

Clinicians and Patients Confront Practical Issues in Wilson Disease

pcbimg

pcbimg

Hepatocellular Carcinoma (HCC) Surveillance Beyond the Guidelines:

pcbimg

Expert Perspectives on PBC: Interactive Management Algorithm and Chatbot

pcbimg

Sex and Gender Disparities in Liver Disease

Gender and sex are two terms that are widely used interchangeably but, when pertaining to clinical research and as detailed in Table 1,1 should be separate and distinct. As shown in the table, sex-based research demonstrates its effect on disease onset, risk factors, prevalence, severity, signs and symptoms, and drug pharmacokinetics and pharmacodynamics. Research on gender has brought to light such important issues as gender inequality, gender stereotypes, and discrimination, which affect patients’ lives and well-being.

pcbimg

Daily Updates Of Featured Abstracts and Articles

Complications of Cirrhosis

View Now

General Liver

View Now

HBV

View Now

HCC

View Now

HCV

View Now

HDV

View Now

HE

View Now

HRS

View Now

MASH

View Now

PBC

View Now

Pediatric Liver Disease

View Now

PH

View Now

Wilsons Disease

View Now

Download our Mobile App and start using it now

app

appbg

Be the first to know about our latest upcoming programs and events!